The tendency of embryonic and induced pluripotent stem cells to form teratomas is a major factor hindering their development as human therapies. Intent on developing a way to sift out the tumor-forming, pluripotent cells from a hodgepodge cell culture, researchers have identified a cocktail of three antibodies that specifically bind to undifferentiated cells. Their findings were published this week in Nature Biotechnology.

While two of these antibodies were already commercially available, the researchers generated a third antibody, which they named stage-specific embryonic antigen-5 (SSEA-5), to bind to glycan molecules found only in early embryonic pluripotent cells. Used in conjunction, the three antibodies removed most tumorigenic cells from culture, although the researchers still observed abnormal growth in the resulting cell mix, Science Codex reports.

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!